妊娠糖尿病患者血清、脐血及胎盘组织中 Visfatin和 Chemerin的表达与胰岛素抵抗发生机制的研究

目的　探讨妊娠糖尿病（ gestational diabetes mellitus，GDM）患者血清、脐血及胎盘组织中的内脏脂肪组织（Visfatin）、脂肪因子趋化素（ Chemerin）的表达变化及与患者发生胰岛素抵抗的关系。方法　选取阜阳市人民医院 2018年 12月～ 2020年 4月妊娠分娩的 GDM孕妇 100例作为 GDM组、糖耐量正常孕妇 100例作为 NGT组。统计分析两组的一般资料、血糖指标、血脂指标，检测两组研究对象血清、脐血、胎盘组织中的 Visfatin，Chemerin表达水平，分析 Visfatin，Chemerin表达与胰岛素抵抗指数（ HOMA-IR）的相关性；通过重组慢病毒载体构建 Visfatin， Chemerin过表达的 3T3-L1脂肪细胞，分析 Visfatin，Chemerin过表达对 3T3-L1脂肪细胞增殖、葡萄糖消耗量、 Akt及 pAkt蛋白表达的影响。结果　GDM 组的 FPG(5.84±0.52mmol/L)，Fins(18.96±3.75μU/ml)，HbA1c(6.42%±0.89%)， HOMA-IR(2.48±0.66)，TC(5.22±0.57mmol/L)和 TG(2.41±0.43mmol/L)测定值均高于 NGT组 (4.61±0.40mmol/L，     

子痫前期孕妇血清 SOCS3，PP-13，GATA-3水平变化及其预测价值研究

目的　探讨血清细胞因子信号转导负调控因子 -3（SOCS-3）、胎盘蛋白 -13(PP-13)、GATA结合蛋白 3(GATA-     

空腹血糖与TG/HDL-C 对非糖尿病患者并发COVID-19 的预测价值研究

目的　探究空腹血糖与三酰甘油/ 高密度脂蛋白胆固醇(triglyceride/high density lipoprotein cholesterol, TG/HDL-C) 比值在对糖尿病患者并发新型冠状病毒肺炎(coronavirus disease 2019, COVID-19) 的预测价值。方法　连续收集2021 年12 月～ 2022 年1 月西安市第四医院收治的非糖尿病并发COVID-19 患者39 例，通过倾向性评分匹配同期西安交通大学第二附属医院健康体检者34 例( 健康对照组)，比较两组间临床特征与实验室检验指标，Logistic 回归及受试者工作特征(receiver operating characteristic, ROC) 曲线分析空腹血糖与TG/HDL-C 对非糖尿病患者并发COVID-19 的预测价值。结果　COVID-19 患者均为轻型(30 例) 或普通型(9 例)，整体症状较轻，中位年龄29.0 (20.0, 49.0) 岁，男性24 例(61.5%)，临床预后较好。COVID-19 患者入院时空腹血糖(4.30±0.47 mmol/L) 与HDL-C[1.07(0.86, 1.30) mmol/L]较健康对照组[5.15±0.70 mmol/L, 2.24(1.77, 3.05) mmol/L] 显著降低，差异具有统计学意义(t=6.277, P ＜ 0.001；Z =-6.026,P＜0.001)，而低密度脂蛋白胆固醇(low density lipoprotein cholesterol, LDL-C) [2.40(1.81, 2.91) mmol/L] 与TG/HDL-C [0.91(0.54, 1.52)] 较健康对照组[1.11 (0.99, 1.30) mmol/L, 0.54 (0.33, 0.90)] 显著升高，差异具有统计学意义(Z=-6.271, -2.801,均P ＜ 0.005)。Logistic 回归分析显示入院时空腹血糖可能是非糖尿病患者感染COVID-19 的独立保护因素(OR :0.020,95% CI: 0.003 ～ 0.150)，TG/HDL-C 升高可能是COVID-19 发病的独立危险因素(OR :4.802, 95% CI: 1.249 ～ 18.460)。ROC 曲线结果显示，空腹血糖与TG/HDL-C 能较好地预测COVID-19 发病风险，曲线下面积(area under curve, AUC) 分别为0.871 和0.708，二者联合诊断的AUC 为0.895。结论　空腹血糖降低与TG/HDL-C 升高可能是非糖尿病人群并发COVID-19 的危险因素，对COVID-19 发病具有较好的预测价值。     

子野个数限值对宫颈癌固定野调强放疗计划的影响

目的:分析子野个数限值对宫颈癌固定野调强放疗（fixed-field intensity-modulated radiotherapy,ff-IMRT）计划的影响，寻求最优的子野个数限值。方法:选取10例接受ff-IMRT的宫颈癌患者，基于Monaco 5.11.03计划系统，以45 Gy/25 f处方剂量分别对同一患者设计8种ff-IMRT计划（ff-IMRT计划依据子野个数限值命名，子野个数限值分别为40、60、70、80、100、120、130、150），采用SPSS 20.0软件比较除plan100之外7个ff-IMRT计划与plan100剂量学参数、优化时间和治疗参数的差异。结果:8种ff-IMRT计划归一化后，plan40和plan60的D2%、Dmin、CI和HI均劣于plan100（P＜0.05）。8种ff-IMRT计划均能较好保护危及器官（organ at risk,OAR）和正常组织。plan40小肠V45;plan40和plan60小肠D2cc，直肠、膀胱V45、D40%，两侧股骨头V40和正常组织 V35、V40均高于plan100（P＜0.05）。plan40和plan60优化时间、治疗参数均优于plan100（P＜0.05）；plan120、plan130和plan150子野面积、子野个数（51~150 cm2和＞150 cm2）和出束时间均劣于plan100（P＜0.05）。结论:子野个数限值为70~100时，ff-IMRT计划能兼顾剂量学参数满足临床要求、优化时间和治疗参数最优化，建议在设计宫颈癌ff-IMRT计划时在该范围内设置子野个数限值。     

Clinical Effectiveness of Erlova in EGFR-Mutated Non-Small Cell Lung Cancer: An Affordable Price with Clinical Benefit

Background: Thyrosin kinase inhibitors (TKIs) is approved for the first line treatment of non-small cell lung cancer (NSCLC) patients with  epidermal growth factor receptor (EGFR) mutation. This study performed to assess clinical effectiveness and safety of Erlova (generic form of Erlotinib). Methods: Somatic mutations of EGFR gene were studied in tumor tissue by polymerase chain reaction (PCR) and bi-directional sequencing in 513 chemonaive and histologically verified lung adenocarcinoma Iranian patients. Patients  with EGFR mutation received Erlova at 150 mg/day  as first line treatment. Primary endpoint was progression free survival (PFS). Results: About 21% (n=109) cases had EGFR mutation. Most EGFR mutations were  occurred at exon 19. Among them, sixty nine patients treated with Erlova. Median PFS was 11.4 months and objective response rate (ORR) was about  88%. Most frequent treatment related adverse events was  skin rash. Conclusion: Our findings showed Erlova had remarkable effectiveness. In  mutation-positive patients with EGFR, Erlova can be used  safely instead of  other tyrosine-kinase inhibitors.     

厦门市社区老年慢性病共病与不良生活方式共存现状研究

目的 调查社区老年人常见的14种慢性病共病情况及不良生活方式共存现象。 方法 采用方便抽样的方法抽取厦门市社区906例老年人群为研究对象,使用自设问卷调查研究对象的慢病共存及不良方式共存现象,使用检验和多因素logistic回归方法进行分析。结果 共纳入906例老年人,慢性病患病率为79.5%,老年人慢性病共病患病率为58.9%。主要的不良生活方式是BMI异常(46.8%)、饮酒(40.5%)、睡眠时间少(37.9%)、缺乏锻炼(35.2%)、吸烟(32.8%)等。多因素logistic回归分析显示,女性(OR=2.232,95%CI:1.474～3.380,P＜0.001)、高龄(OR=2.038,95%CI:1.234～3.365,P=0.001)、有慢性病家族史(OR=2.854,95%CI:1.943～4.194,P＜0.001)、肥胖(OR=2.571,95%CI:1.096～6.033,P=0.030)、饮酒(OR=3.582,95%CI:2.531～5.071,P＜0.001)、吸烟(OR=1.789,95%CI:1.172～2.732,P=0.007)、嗜盐(OR=1.818,95%CI:1.170～2.823,P=0.008)、嗜油(OR=2.023,95%CI:1.153～3.550,P=0.010)、睡眠质量差(OR=2.091,95%CI:1.360～3.215,P=0.001)的老年人,慢性病共病的比例高。 结论 厦门市社区老年人慢性病共病和不良生活方式共存现象严重。肥胖、饮酒、吸烟、嗜盐、嗜油、睡眠质量差等行为生活方式是慢性病重要的可干预因素,社区工作者应提高社区居民对健康生活方式重要性的认识,促使其主动改变不良生活方式并长期坚持健康的生活方式,以降低其慢性病的发病风险,减少其伤残程度,提高生活质量。     

原发性肺鳞癌中EGFR和ALK基因突变的临床研究北大核心

目的:探讨赣南地区原发性肺鳞癌患者EGFR和ALK基因突变的特点,科学指导此类患者优选靶向用药。方法:入组73例原发性肺鳞癌病例,采用ARMS-PNA技术检测EGFR基因第18、19、20、21外显子突变,应用不平衡法检测其中60例病例的ALK融合基因,回顾性分析EGFR和ALK基因突变患者的临床病理特征。结果:EGFR基因突变8例,阳性率为10.96%(8/73),4例为L858R突变,3例为19del突变,1例为G719X突变。女性患者突变率(66.67%,2/3)明显高于男性患者(8.57%,6/70)(P=0.030),EGFR基因突变在高龄(≥60岁)、进展期(N_(1-3)、Ⅲ+Ⅳ期)患者中相对较高,但差异无统计学意义(P>0.05)。EGFR基因突变与吸烟史、T分期以及肿瘤分布位置均无相关性(P>0.05);ALK融合基因表达2例,阳性率3.33%(2/60),与患者性别、年龄、吸烟史、TNM分期及肿瘤分布类型等各临床病理特征均无相关性(P>0.05);未发现EGFR和ALK基因共存突变病例。结论:赣南地区原发性肺鳞癌患者EGFR和ALK基因突变率相对不高,EGFR基因突变以L858R和19del突变为主,且好发于女性患者,可能是患者病情进展的预测因子之一。     

Predictors of Chemotherapy Induced Adverse Events in Pediatric Osteosarcoma Patients

Objective: To investigate the prevalence of chemotherapy-induced adverse events and the associated risk factors in pediatric patients with osteosarcoma. Methods: This retrospective cross-sectional study enrolled 90 pediatric osteosarcoma patients (with 1,017 chemotherapy cycles) treated at Srinagarind Medical Center, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand, between January 1, 2008 and December 31, 2018. The prevalence of major adverse events and a correlation between baseline characteristics and adverse events were analyzed using a generalized estimating equation model. Result: The prevalence of adverse events in 90 pediatric osteosarcoma patients (with 1,017 chemotherapy cycles) was determined as chemotherapy-induced nausea and vomiting (29.2%; n=296), hepatotoxicity (21.2%; n=215), anemia (70.69%; n=719), neutropenia (26.65%; n=271), and thrombocytopenia (13.65%; n=139). Factors associated with chemotherapy-induced hepatotoxicity included methotrexate dose ≥ 12 g/m2 (odds ratio [OR] 1.30; 95% confidence interval [CI] 1.22–1.39; P<0.001), plasma concentration of methotrexate at 72 hours >0.1 μM (OR 1.22; 95% CI 1.19–1.25; P<0.001), and pre-hydration rate ≤ 125 mL/m2/h (OR 1.10; 95% CI 1.07–1.12; P<0.001). Conclusion: Major adverse events are becoming more common in pediatric osteosarcoma patients, and risk factors include larger chemotherapy doses, higher plasma methotrexate concentrations, and a slower pre-hydration rate. The outcomes of the study could aid in the better treatment of toxicity in children with osteosarcoma.     

Antitumor Activity of Choerospondias axillaris Fruit Extract by Regulating the Expression of SNCAIP and SNCA on MDA-MB-231 Cells

Objective: Cancer is a huge problem of disease globally. Today, the percentage of people die from cancer is more than a combination of various diseases. In females, most common types of malignancies that occur are breast and cervical. The present focus has been shifted on medicinal plants as a form of therapy and there is a constant need to identify new therapeutic agents. Choerospondias axillaris (C. axillaris), an underutilized fruit, has been used in the remedy of various diseases. In the present communication, we evaluated the molecular mechanism of C. axillaris methanol extract in regulating cell death in human breast cancer cells (MDA-MB-231). Methods: Methanol extract of C. axillaris was prepared and compounds were screened by Gas chromatography-mass spectrometry. The effect of fruit extract was determined on MDA-MB-231 cells by MTT ((3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay and to analyse the molecular mechanism of human breast cancer cells after treating with fruit extract, protein profiling study was performed by two-dimensional gel electrophoresis. Results: A total 9 differentially expressed proteins were identified by matrix-assisted laser desorption/ionization-time of flight mass spectrometry (MALDI-TOF-MS/MS) analysis. Among 9 identified proteins, synphilin-1 protein was found to be significantly downregulated, validated by western blot and RT-qPCR analysis. Possible interacting partners of synphilin-1 (SNCAIP) were analyzed for their possible role in cancer by the in-silico method. Conclusion: Our data implicate that the presence of bioactive compound(s) in C. axillaris fruits might play an important role in inhibiting the proliferation of breast carcinoma cells and Synphilin-1 protein may play a role of apoptotic function.